Journal of cannabis research最新文献

{"title":"Attitudes of Swiss psychiatrists towards cannabis regulation and medical use in psychiatry: a cross-sectional study.","authors":"Constantin Strube, Renato Davide Comazzi, Dimitri Löwinger, Reto Auer, Franz Moggi, Philippe Pfeifer","doi":"10.1186/s42238-023-00210-y","DOIUrl":"10.1186/s42238-023-00210-y","url":null,"abstract":"<p><strong>Background: </strong>Changes in regulation for cannabis for nonmedical use (CNMU) are underway worldwide. Switzerland amended the law in 2021 allowing pilot trials evaluating regulative models for cannabis production and distribution. Simultaneously, cannabis for medical use (CMU) in psychiatry is a growing issue, asked for by patients and being discussed by medical professionals.</p><p><strong>Methods: </strong>From December 2021 to February 2022, we conducted an online survey of psychiatrists in Switzerland. The survey comprised questions on attitudes towards regulative models for CNMU and towards prescribing CMU for mental disorders.</p><p><strong>Results: </strong>We contacted 2010 psychiatrists in Switzerland. A total of 274 (14%) participated in the survey. Sixty-four percent agreed to a regulated legalization of CNMU, and 89% would welcome pilot trials in Switzerland assessing models for regulating CNMU with those from a French-speaking region being more skeptical. Forty-nine percent of psychiatrists agree that CMU might have a therapeutic effect in mental disorders, but 50% agree that there is not enough scientific evidence yet. Participants working in an inpatient setting or in a French-speaking region as well as those with a longer duration of practice were more skeptical on CMU for mental health.</p><p><strong>Conclusions: </strong>Most surveyed Swiss psychiatrists favor the regulation of CNMU and the conduct of pilot trials. Despite little evidence and potential negative consequences, many participating Swiss psychiatrists agreed that cannabis could be efficacious in the treatment of some mental disorders advocating for more research in this topic.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10699035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138500663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis and pathologies in dogs and cats: first survey of phytocannabinoid use in veterinary medicine in Argentina.","authors":"Diana Banach, Paola Ferrero","doi":"10.1186/s42238-023-00209-5","DOIUrl":"10.1186/s42238-023-00209-5","url":null,"abstract":"<p><strong>Background: </strong>In animals, the endocannabinoid system regulates multiple physiological functions. Like humans, animals respond to preparations containing phytocannabinoids for treating several conditions. In Argentina, laws 27350 and 27669 have expanded the possibility of studying beneficial and adverse effects.</p><p><strong>Materials and methods: </strong>We conducted a web-based survey of Argentinian Cannabis Veterinarians to make a situational diagnosis on the number of veterinary medicine professionals currently developing treatments with cannabinoids focusing on dogs and cats.  RESULTS: Among the species treated, 77% corresponded to dogs, while 21% were cats. Pain, seizures, and behavior disorders are the most prevalent conditions in dogs. Seven conditions and combinations were treated in cats. Full-spectrum cannabis extract derived from three different chemotypes was administered alone or with standard medication. Response to cannabis treatment was characterized based on improvement categorized according to clinical assessment. Both dogs and cats showed different improvement grades in clinical signs.</p><p><strong>Conclusion: </strong>This analysis provides promising results regarding the medicinal use of cannabis in dogs and cats. Based on this analysis, we propose to expand the training of professionals, obtain quality preparations, and initiate controlled trials to reinforce knowledge of the use of cannabinoids in veterinary medicine.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":null,"pages":null},"PeriodicalIF":4.1,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The holistic effects of medical cannabis compared to opioids on pain experience in Finnish patients with chronic pain.","authors":"Jussi Jylkkä, Aleksi Hupli, Aleksandra Nikolaeva, Sandra Alanen, Anna Erika Back, Sara Lindqvist, Andreas Krabbe, Maya Lavie-Ajayi, Oskari Kantonen","doi":"10.1186/s42238-023-00207-7","DOIUrl":"10.1186/s42238-023-00207-7","url":null,"abstract":"<p><strong>Background: </strong>Medical cannabis (MC) is increasingly used for chronic pain, but it is unclear how it aids in pain management. Previous literature suggests that MC could holistically alter the pain experience instead of only targeting pain intensity. However, this hypothesis has not been previously systematically tested.</p><p><strong>Method: </strong>A retrospective internet survey was used in a sample of Finnish chronic pain patients (40 MC users and 161 opioid users). The patients evaluated statements describing positive and negative phenomenological effects of the medicine. The two groups were propensity score matched to control for possible confounding factors.</p><p><strong>Results: </strong>Exploratory factor analysis revealed three experience factors: Negative Side Effects, Positive Holistic Effects, and Positive Emotional Effects. The MC group (matched n = 39) received higher scores than the opioid group (matched n = 39) in Positive Emotional Effects with large effect size (Rank-Biserial Correlation RBC = .71, p < .001), and in Holistic Positive Effects with medium effect size (RBC = .47, p < .001), with no difference in Negative Side Effects (p = .13). MC and opioids were perceived as equally efficacious in reducing pain intensity. Ratings of individual statements were exploratively examined in a post hoc analysis.</p><p><strong>Conclusion: </strong>MC and opioids were perceived to be equally efficacious in reducing pain intensity, but MC additionally positively affected broader pain-related factors such as emotion, functionality, and overall sense of wellbeing. This supports the hypothesis that MC alleviates pain through holistically altering the pain experience.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71524004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The potential for Ghana to become a leader in the African hemp industry.","authors":"Richard Quansah Amissah","doi":"10.1186/s42238-023-00205-9","DOIUrl":"10.1186/s42238-023-00205-9","url":null,"abstract":"<p><strong>Background: </strong>Global interest in hemp cultivation and utilization is on the rise, presenting both challenges and opportunities for African countries. This article focuses on Ghana's potential to establish a thriving hemp sector, considering its favorable climate, abundant agricultural resources, and existing policies and programs that support the growth and advancement of the agricultural sector, as well as agro-processing and value addition.</p><p><strong>Main body: </strong>Ghana's recent decriminalization of cannabis with low tetrahydrocannabinol (THC) levels marks a progressive step, unlocking opportunities for research, commercial production, and innovation in hemp-related sectors. This regulatory change paves the way for the development of textiles, construction materials, and wellness products derived from hemp. However, the African hemp industry faces various simultaneous challenges, including pest management, absence of regulatory frameworks, limited research, inadequate infrastructure, and lack of access to finance and investment capital for small-scale farmers. Fortunately, several countries that have legalized hemp cultivation and processing have found innovative solutions to these challenges through the use of integrated pest management strategies, establishing collaborations with international standards organizations, implementing public-private partnerships, offering tax incentives for investors, and providing low-interest loans and credit facilities for small-scale farmers. Ghana can draw inspiration from these successful approaches and adapt them to its own context to foster the growth of the hemp industry.</p><p><strong>Conclusion: </strong>By capitalizing on its strengths and addressing the challenges it is likely to face while developing its hemp industry, Ghana can position itself as a leader in the African hemp industry. This position of leadership would not only drive economic growth, but also create job opportunities and foster sustainable development through responsible hemp cultivation and utilization.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71416490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabinoid hyperemesis syndrome presenting with ventricular bigeminy.","authors":"Jeffrey Wong, Muneet Gill, Thor Stead, Derrick Huang, Latha Ganti","doi":"10.1186/s42238-023-00203-x","DOIUrl":"10.1186/s42238-023-00203-x","url":null,"abstract":"<p><p>The is a case of a 28-year-old male presenting to an emergency department (ED) via emergency medical services (EMS) with a chief complaint of \"gastritis.\" He was noted to have bigeminy on the pre-arrival EMS electrocardiogram. He was ultimately diagnosed with cannabinoid hyperemesis syndrome (CHS). CHS is becoming an exceedingly common emergency department presentation due to the poorly regulated but widespread availability of cannabis products. The authors discuss a case of CHS and ventricular bigeminy.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49687295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}